X
KEY PRODUCTS
Details:
New pre-clinical study showed that Dermial® hyaluronic acid matrix ingredient increased type I collagen production by almost half – an observation not seen with standard hyaluronic acid from fermentation or extraction origin.
Lead Product(s): Hyaluronic Acid,Dermatan Sulfate,Collagen
Therapeutic Area: Dermatology Product Name: Dermial
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
Details:
By partnering with Bioiberica, ByHealth aims to capitalise on the untapped potential of new product development with native type II collagen and respond to the growing number of consumers looking to support their mobility with effective, convenient products across the country.
Lead Product(s): Undenatured Type II Collagen
Therapeutic Area: Musculoskeletal Product Name: Collavant n2
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: ByHealth
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 11, 2022
Details:
Bioiberica’s native (undenatured) type II collagen, Collavant® n2 (previously b2-Cool®) and the addition of Tendaxion® - a new brand for its tendon health ingredient.
Lead Product(s): Chondroitin Sulfate
Therapeutic Area: Musculoskeletal Product Name: CSbioactive
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2021
Details:
Apsen’s Motilex HA combines two leading ingredients, b-2Cool native type II collagen and Mobilee, patented ingredient that synergistically combines a high concentration of hyaluronic acid with polysaccharides and collagen, to effectively maintain joint function.
Lead Product(s): Hyaluronic Acid,Type II Collagen
Therapeutic Area: Musculoskeletal Product Name: Motilex HA
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apsen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 26, 2021
Details:
The study, conducted in a rabbit model of osteoarthritis, set out to evaluate the effects of b-2Cool native type II collagen in combination with CS b-Bioactive chondroitin sulphate, glucosamine hydrochloride and Mobilee® which is a rooster comb extract rich in hyaluronic acid.
Lead Product(s): Undenatured Type II Collagen,Chondroitin Sulfate,Hyaluronic Acid
Therapeutic Area: Musculoskeletal Product Name: Mobilee
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2020
Details:
B-2Cool (Bioiberica’s native type II collagen) is an innovative ingredient, has been shown in four scientific studies to help maintain good joint health at a very low daily dose.
Lead Product(s): Undenatured Type II Collagen,Harpagophytum Procumbens Extract,Hyaluronic Acid
Therapeutic Area: Musculoskeletal Product Name: Colnatur Forte
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
Nestlé Health Science is incorporating Bioiberica’s patented ingredient, Mobilee®, into its MERITENE® Mobilis® joint-health drink mix.
Lead Product(s): Hyaluronic Acid,Type II Collagen,Polysaccharide
Therapeutic Area: Musculoskeletal Product Name: Meritene Mobilis
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Nestle Health Sciences SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 16, 2020
Details:
Under the terms of the agreement, Bayer Animal Health will distribute and market selected products from Bioiberica´s Companion Animal Health portfolio in eight countries.
Lead Product(s): Chondroitin Sulfate,Glucosamine,Hyaluronic Acid
Therapeutic Area: Musculoskeletal Product Name: Condrovet
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
